Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease

Area of Science:

• Immunology
• Metabolism
• Mitochondrial Biology

Background:

• Mitochondria are central to metabolic reprogramming in immune responses and inflammation.
• Colitogenic T cells and inflammatory bowel disease (IBD) involve key metabolic pathways like glycolysis, pyruvate oxidation, and glutaminolysis.
• Mitochondrial dysfunction is increasingly recognized in IBD pathogenesis.

Purpose of the Study:

• To review current knowledge on metabolic reprogramming in colitogenic T cells.
• To discuss mitochondrial dysfunctions in colitogenic T cells relevant to IBD.
• To explore potential therapeutic applications for IBD targeting these cellular processes.

Main Methods:

• Review of existing literature on T cell metabolism and mitochondrial function in IBD.
• Analysis of studies investigating glycolysis, pyruvate oxidation, and glutaminolysis in colitogenic T cells.
• Examination of evidence for mitochondrial dysfunction markers (e.g., mROS, respiration, biogenesis) in IBD models.

Main Results:

• Colitogenic T cells undergo metabolic reprogramming, enhancing glycolysis, pyruvate oxidation, and glutaminolysis.
• These metabolic shifts contribute to increased inflammatory cytokine production and tissue damage in IBD.
• Colitogenic T cells exhibit impaired mitochondrial respiration, elevated mitochondrial reactive oxygen species (mROS), altered calcium homeostasis, and defective mitochondrial biogenesis.

Conclusions:

• Metabolic reprogramming and mitochondrial dysfunction are critical in colitogenic T cells and IBD pathogenesis.
• Targeting these mitochondrial and metabolic pathways presents promising therapeutic avenues for IBD.
• Evidence from animal models supports the potential of these strategies for IBD treatment.